Pasireotide
Ductal Carcinoma in Situ
NYU Langone Healthprotein_peptidePhase 1/2Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 89/ 100
Competitive context
25 Active assets in the Ductal Carcinoma in Situ cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ROPIVACAINE Zealand University Hospital | Phase 4 | BB |
SUFENTANYL Zealand University Hospital | Phase 4 | BB |
TAMOXIFEN Northwestern University | Phase 3 | BB |
Metformin M.D. Anderson Cancer Center | Phase 3 | BB |
TAMOXIFEN National Cancer Institute (NCI) | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Pasireotide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →